Aliases & Classifications for Speech Disorder

MalaCards integrated aliases for Speech Disorder:

Name: Speech Disorder 12 15
Speech Disorders 55 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:92
MeSH 44 D013064
NCIt 50 C5041
ICD10 33 R47
UMLS 73 C0037822

Summaries for Speech Disorder

Disease Ontology : 12 A communication disorder that involves difficulty with the act of speech production.

MalaCards based summary : Speech Disorder, also known as speech disorders, is related to epilepsy, focal, with speech disorder and with or without mental retardation and mutism, and has symptoms including cluttering, aprosodia and scanning speech. An important gene associated with Speech Disorder is GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A), and among its related pathways/superpathways are Lysosome and Nicotine addiction. The drugs Memantine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, tongue and cortex, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 76 Speech disorders or speech impediments are a type of communication disorder where \'normal\' speech is... more...

Related Diseases for Speech Disorder

Diseases related to Speech Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 epilepsy, focal, with speech disorder and with or without mental retardation 34.0 GRIN2A GRIN2B LOC105371077
2 mutism 30.9 CNTNAP2 GRN
3 stuttering 30.4 CNTNAP2 FOXP2 GNPTAB GNPTG NAGPA
4 aphasia 28.9 FOXP2 GRIN2A GRN
5 speech and communication disorders 28.5 CNTNAP2 FOXP2 GNPTG GRIN2A GRN NAGPA
6 autism 28.3 CNTNAP2 FOXP1 FOXP2 GRIN2A GRIN2B
7 articulation disorder 27.8 CNTNAP2 FOXP2 GNPTAB GNPTG NAGPA SLC17A5
8 grin2a-related speech disorders and epilepsy 12.1
9 epilepsy-aphasia spectrum 11.2
10 spondyloepiphyseal dysplasia-brachydactyly and distinctive speech 10.9
11 intellectual deficit buenos-aires type 10.8
12 neurodegeneration with brain iron accumulation 1 10.6
13 inclusion-cell disease 10.6 GNPTAB GNPTG
14 mucolipidosis iii alpha/beta 10.6 GNPTAB GNPTG
15 mucolipidosis ii alpha/beta 10.5 GNPTAB GNPTG
16 ocular dominance 10.5 GRIN2A GRIN2B
17 centralopathic epilepsy 10.5
18 spastic paraplegia 20, autosomal recessive 10.5
19 pontine tegmental cap dysplasia 10.5
20 echolalia 10.5
21 fetal alcohol spectrum disorder 10.4 GRIN2A GRIN2B
22 fetal alcohol syndrome 10.4 GRIN2A GRIN2B
23 childhood apraxia of speech 10.4 CNTNAP2 FOXP2
24 d-2-hydroxyglutaric aciduria 1 10.3 GRIN2A GRIN2B
25 valproate embryopathy 10.3 GRIN2A GRIN2B
26 reading disorder 10.3 CNTNAP2 FOXP2
27 benign epilepsy with centrotemporal spikes 10.1 CNTNAP2 FOXP2 GRIN2A
28 focal epilepsy 10.1 CNTNAP2 GRIN2A GRIN2B
29 schizophrenia 10.0
30 autism spectrum disorder 9.9 CNTNAP2 FOXP2 GRIN2B
31 microcephaly 9.8
32 epilepsy 9.8
33 disease of mental health 9.7 GRIN2A GRIN2B GRN
34 specific language impairment 9.6 CNTNAP2 FOXP2
35 amyotrophic lateral sclerosis 1 9.6
36 ankyloglossia 9.6
37 cleft palate, isolated 9.6
38 multiple system atrophy 1 9.6
39 treacher collins syndrome 1 9.6
40 otitis media 9.6
41 velocardiofacial syndrome 9.6
42 friedreich ataxia 1 9.6
43 galactosemia 9.6
44 histidinemia 9.6
45 mental retardation, buenos aires type 9.6
46 cognitive function 1, social 9.6
47 asthma 9.6
48 supranuclear palsy, progressive, 1 9.6
49 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 9.6
50 alacrima, achalasia, and mental retardation syndrome 9.6

Graphical network of the top 20 diseases related to Speech Disorder:



Diseases related to Speech Disorder

Symptoms & Phenotypes for Speech Disorder

UMLS symptoms related to Speech Disorder:


cluttering, aprosodia, scanning speech, other and unspecified speech disturbances, dysglossia, rhinolalia, other speech disturbances

MGI Mouse Phenotypes related to Speech Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 CNTNAP2 GNPTAB GRIN2A GRIN2B GRN KANSL1
2 nervous system MP:0003631 9.23 CNTNAP2 GNPTAB GRIN2A GRIN2B GRN KANSL1

Drugs & Therapeutics for Speech Disorder

Drugs for Speech Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Natalizumab Approved, Investigational Phase 4 189261-10-7
4
Citalopram Approved Phase 4 59729-33-8 2771
5
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
8 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
9 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
10 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
12 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
13 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
14 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Dopamine agonists Phase 4,Not Applicable
18 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
19 Cholinergic Agents Phase 4,Phase 2,Not Applicable
20 Serotonin Agents Phase 4
21 Cholinesterase Inhibitors Phase 4,Phase 2,Not Applicable
22 Serotonin Uptake Inhibitors Phase 4
23 Neurotransmitter Uptake Inhibitors Phase 4
24 Antidepressive Agents Phase 4,Phase 1,Phase 2
25 Antidepressive Agents, Second-Generation Phase 4
26 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
28 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
29 Radiopharmaceuticals Phase 4,Phase 2
30 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
31
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
32
Methylene blue Approved, Investigational Phase 3 61-73-4
33
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
34
Miglustat Approved Phase 3,Phase 1 72599-27-0 51634
35
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 50-02-2 5743
37
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3 50-24-8 5755
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3 83-43-2 6741
41
Tenecteplase Approved Phase 3,Phase 2 191588-94-0
42
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
43
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
44
Asenapine Approved Phase 3 85650-56-2, 65576-45-6 3001386
45 tannic acid Approved, Nutraceutical Phase 3
46
1-Deoxynojirimycin Experimental Phase 3 19130-96-2 1374
47 Ecopipam Investigational Phase 2, Phase 3 112108-01-7
48 Neuroprotective Agents Phase 3,Phase 2,Phase 1
49 Prednisolone acetate Phase 2, Phase 3,Phase 3
50 Dexamethasone acetate Phase 2, Phase 3,Phase 3 1177-87-3

Interventional clinical trials:

(show top 50) (show all 335)
# Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
7 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
8 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
11 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
12 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
13 Randomized Clinical Trial of Phonological Interventions Unknown status NCT00818428 Phase 2, Phase 3
14 AM-111 in the Treatment of Acute Inner Ear Hearing Loss Completed NCT02561091 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
15 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
16 A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering Completed NCT00830154 Phase 2, Phase 3 pagoclone
17 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
18 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
19 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
20 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
21 Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Recruiting NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
22 Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Recruiting NCT02111785 Phase 2, Phase 3 Dexamethasone
23 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion Recruiting NCT02398656 Phase 3 Tenecteplase;Antiplatelet treatment
24 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
25 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
26 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
27 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
28 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering Suspended NCT01684657 Phase 3 Asenapine
29 Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment Terminated NCT02809118 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
30 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
31 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
32 Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study Unknown status NCT02540109 Phase 2
33 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
34 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
35 Follow-up of Children After Stuttering Treatment Unknown status NCT00709072 Phase 2
36 Spacing Lidcombe Program Clinic Visits Unknown status NCT00680303 Phase 2
37 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
38 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
39 Efficacy of Voice Treatment for Parkinson's Disease Unknown status NCT00123084 Phase 2
40 Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients Completed NCT01255358 Phase 2 Dexamethasone
41 TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion Completed NCT01654445 Phase 2 Tenecteplase
42 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2 EGb 761 120 mg;Placebo
43 Long-Term Assessment of Remyelinating Therapy Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
44 Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Completed NCT00977665 Phase 2 rasagiline mesylate;placebo
45 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
46 Randomised Controlled Treatment Study of Selective Mutism Completed NCT01002196 Phase 2
47 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
48 Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS) Completed NCT00239915 Phase 2 Pagoclone
49 EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study Completed NCT00216255 Phase 2 Pagoclone;Placebo
50 Brief Behavioral Treatment for Anxiety in Young Children Completed NCT02051192 Phase 1, Phase 2

Search NIH Clinical Center for Speech Disorder

Cochrane evidence based reviews: speech disorders

Genetic Tests for Speech Disorder

Anatomical Context for Speech Disorder

MalaCards organs/tissues related to Speech Disorder:

41
Brain, Tongue, Cortex, Testes, Liver, Bone, Eye

Publications for Speech Disorder

Articles related to Speech Disorder:

(show top 50) (show all 81)
# Title Authors Year
1
Identification of a novel homozygous TRAPPC9 gene mutation causing non-syndromic intellectual disability, speech disorder, and secondary microcephaly. ( 29031008 )
2017
2
Two unrelated children with overlapping 6q25.3 deletions, motor speech disorders, and language delays. ( 28767196 )
2017
3
Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. ( 27310289 )
2016
4
Asthma, hay fever and food allergy are associated with caregiver-reported speech disorders in US children. ( 27091599 )
2016
5
Feasibility of Technology Enabled Speech Disorder Screening. ( 27440284 )
2016
6
Neurophysiologic markers of primary motor cortex for laryngeal muscles and premotor cortex in caudal opercular part of inferior frontal gyrus investigated in motor speech disorder: a navigated transcranial magnetic stimulation (TMS) study. ( 27130564 )
2016
7
Eczema Is Associated with Childhood Speech Disorder: A Retrospective Analysis from the National Survey of Children's Health and the National Health Interview Survey. ( 26520915 )
2015
8
Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. ( 25683763 )
2015
9
Psychogenic speech disorder--a case report. ( 26417806 )
2015
10
Motor Speech Disorders Associated with Primary Progressive Aphasia. ( 25309017 )
2014
11
Detection of chromosomal breakpoints in patients with developmental delay and speech disorders. ( 24603971 )
2014
12
Effectiveness of tongue-tie division for speech disorder in children. ( 25142274 )
2014
13
Vowel acoustics in dysarthria: speech disorder diagnosis and classification. ( 24687467 )
2014
14
Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. ( 25348587 )
2014
15
Correlation of otologic complaints in soldiers with speech disorders after traumatic brain injury. ( 24275459 )
2014
16
Motor and speech disorders in classic galactosemia. ( 23546812 )
2013
17
The interaction between awareness of one' s own speech disorder with linguistics variables: distinctive features and severity of phonological disorder. ( 24408546 )
2013
18
A Variability-Generating Circuit Goes Awry in a Songbird Model of the FOXP2 Speech Disorder. ( 24360538 )
2013
19
Effects of social cognitive impairment on speech disorder in schizophrenia. ( 22416265 )
2013
20
On identifying the processes underlying schizophrenic speech disorder. ( 21562141 )
2012
21
Surgical improvement of speech disorder caused by amyotrophic lateral sclerosis. ( 23171742 )
2012
22
Distinguishing groups of children with persistent speech disorder: findings from a prospective population study. ( 22059376 )
2012
23
Proposal for classifying the severity of speech disorder using a fuzzy model in accordance with the implicational model of feature complexity. ( 22876768 )
2012
24
The prevalence of speech disorder in primary school students in Yazd-Iran. ( 21425069 )
2011
25
The relationship of bottle feeding and other sucking behaviors with speech disorder in Patagonian preschoolers. ( 19845936 )
2009
26
Sequential treatment of speech disorders in velocardiofacial syndrome patients: an 8-year retrospective evaluation. ( 19816377 )
2009
27
Speech disorder screening test for children. ( 19838570 )
2009
28
Foreign accent syndrome as a developmental motor speech disorder. ( 19121521 )
2009
29
[67-year-old patient with speech disorder and dysphagia]. ( 19006046 )
2008
30
An autosomal dominant genetically heterogeneous variant of rolandic epilepsy and speech disorder. ( 18248446 )
2008
31
Not all ACE inhibitor related angioedema is always evident: a case which is misdiagnosed as panic attack and speech disorder. ( 18047821 )
2007
32
Teaching phoneme awareness to pre-literate children with speech disorder: a randomized controlled trial. ( 17514541 )
2007
33
Speech perception and short-term memory deficits in persistent developmental speech disorder. ( 15896836 )
2006
34
Effects of positive affect on speech disorder in schizophrenia. ( 16319708 )
2005
35
Evaluation of speech disorders in children with cleft lip and palate. ( 16044225 )
2005
36
Is slowly progressive anarthria a "pure" motor-speech disorder? Evidence from writing performance. ( 16006336 )
2005
37
Intervention for children with severe speech disorder: a comparison of two approaches. ( 16195201 )
2005
38
Educational consequences of developmental speech disorder: Key Stage 1 National Curriculum assessment results in English and mathematics. ( 15130186 )
2004
39
Is the intensity of Schneiderian symptoms related to handedness and speech disorder in subjects with psychosis? ( 14984875 )
2004
40
A reconsideration of Moses' speech disorder. ( 12706914 )
2003
41
Speech disorder related to tacrolimus-induced pontine myelinolysis after orthotopic liver transplantation. ( 12819864 )
2003
42
Postoperative speech disorder after medial frontal surgery: role of the supplementary motor area. ( 12601097 )
2003
43
The speech disorder of Doc in Walt Disney's "Snow White and the Seven Dwarfs". ( 11468334 )
2001
44
Speech disorder in schizophrenia: review of the literature and exploration of its relation to the uniquely human capacity for language. ( 11596849 )
2001
45
Speech disorder in children with Down's syndrome. ( 11489052 )
2001
46
Risk for speech disorder associated with early recurrent otitis media with effusion: two retrospective studies. ( 10668654 )
2000
47
Is stuttering a speech disorder? ( 10098277 )
1999
48
Growth retardation, distinct oriental-like facies, glaucoma, brachydactyly, ventricular septal defect and speech disorder. An unknown entity. ( 10546095 )
1999
49
[Exclusion of receptive speech disorders with the ADOS (Autism Diagnostic Observation Schedule)]. ( 10637975 )
1999
50
Analysis of speech disorders in acute pseudobulbar palsy: a longitudinal study of a patient with lingual paralysis. ( 9926359 )
1998

Variations for Speech Disorder

Expression for Speech Disorder

Search GEO for disease gene expression data for Speech Disorder.

Pathways for Speech Disorder

Pathways related to Speech Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.01 GNPTAB GNPTG NAGPA SLC17A5
2 10.92 GRIN2A GRIN2B
3 10.72 GRIN2A GRIN2B
4 10.62 GRIN2A GRIN2B
5 10.28 GRIN2A GRIN2B

GO Terms for Speech Disorder

Cellular components related to Speech Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic density membrane GO:0098839 9.16 GRIN2A GRIN2B
2 synaptic membrane GO:0097060 8.96 GRIN2A GRIN2B
3 NMDA selective glutamate receptor complex GO:0017146 8.62 GRIN2A GRIN2B

Biological processes related to Speech Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cerebral cortex development GO:0021987 9.5 CNTNAP2 FOXP2 TRAPPC9
2 lysosome organization GO:0007040 9.48 GNPTAB NAGPA
3 carbohydrate phosphorylation GO:0046835 9.46 GNPTAB GNPTG
4 ionotropic glutamate receptor signaling pathway GO:0035235 9.43 GRIN2A GRIN2B
5 glutamate receptor signaling pathway GO:0007215 9.4 GRIN2A GRIN2B
6 excitatory chemical synaptic transmission GO:0098976 9.37 GRIN2A GRIN2B
7 vocal learning GO:0042297 9.26 CNTNAP2 FOXP2
8 calcium ion transmembrane import into cytosol GO:0097553 9.16 GRIN2A GRIN2B
9 secretion of lysosomal enzymes GO:0033299 8.96 GNPTAB NAGPA
10 N-glycan processing to lysosome GO:0016256 8.62 GNPTAB GNPTG

Molecular functions related to Speech Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen receptor binding GO:0050681 9.37 FOXP1 FOXP2
2 ionotropic glutamate receptor activity GO:0004970 9.32 GRIN2A GRIN2B
3 extracellularly glutamate-gated ion channel activity GO:0005234 9.26 GRIN2A GRIN2B
4 NMDA glutamate receptor activity GO:0004972 9.16 GRIN2A GRIN2B
5 glutamate-gated calcium ion channel activity GO:0022849 8.96 GRIN2A GRIN2B
6 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity GO:0003976 8.62 GNPTAB GNPTG

Sources for Speech Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....